Measurement of plasma levels of C3d and evaluation of C3d/C3 ratio directly [28, 62] or in correlation with known risk CFH variants [63], indicated increased systemic complement activation in AMD patients and provided further evidence of the connection between C3 and AMD. Here, C3 is linked to age-related macular degeneration.